Abscess - Pipeline Review, H2 2011

Global Markets Direct, December 2011, Pages: 46

Abscess – Pipeline Review, H2 2011

Summary

Global Markets Direct’s, 'Abscess - Pipeline Review, H2 2011', provides an overview of the Abscess therapeutic pipeline. This report provides information on the therapeutic development for Abscess, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Abscess. 'Abscess - Pipeline Review, H2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Abscess.
- A review of the Abscess products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Abscess pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Abscess.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Abscess pipeline depth and focus of Abscess therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Abscess Therapeutic Products under Development, Key Players in Abscess Therapeutics, Abscess Pipeline Overview, Abscess Pipeline, Abscess Pipeline Assessment

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Abscess Overview
Therapeutics Development
An Overview of Pipeline Products for Abscess
Abscess Therapeutics under Development by Companies
Abscess Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Abscess Therapeutics – Products under Development by Companies
Abscess Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Abscess Therapeutics Development
Johnson & Johnson
Rib-X Pharmaceuticals, Inc.
Taiho Pharmaceutical Co., Ltd.
Durata Therapeutics Inc.
Abscess – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Dalbavancin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RX-1741 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Oritavancin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Tissue Plasminogen Activator - Drug Profile
Product Description
Mechanism of Action
R&D Progress
JNJ-Q2 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Pasireotide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Moxifloxacin + Metronidazole - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Trimethoprim + Sulfamethoxazole + Clindamycin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
YP-18 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Meropenem - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Abscess Therapeutics – Drug Profile Updates
Abscess – Product Development Milestones
Abscess – Product Development Milestones
Featured News & Press Releases
May 10, 2011: Durata Announces Antibiotic Surveillance Results For Dalbavancin Presented At ECCMID Meeting
Apr 26, 2011: Durata Therapeutics Announces Worldwide Rights For The Development And Commercialization Of Advanced-Stage Antibiotic, Dalbavancin
Apr 19, 2011: Furiex Acquires Full Exclusive License Rights to Develop and Commercialize JNJ-Q2 (fluoroquinolone)
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Abscess, H2 2011
Products under Development for Abscess – Comparative Analysis, H2 2011
Number of Products under Development by Companies, H2 2011
Number of Products under Investigation by Universities/Institutes, H2 2011
Comparative Analysis by Late Stage Development, H2 2011
Comparative Analysis by Mid Clinical Stage Development, H2 2011
Products under Development by Companies, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Johnson & Johnson, H2 2011
Rib-X Pharmaceuticals, Inc., H2 2011
Taiho Pharmaceutical Co., Ltd., H2 2011
Durata Therapeutics Inc., H2 2011
Assessment by Monotherapy Products, H2 2011
Assessment by Combination Products, H2 2011
Assessment by Stage and Route of Administration, H2 2011
Assessment by Molecule Type, H2 2011
Abscess Therapeutics – Drug Profile Updates

List of Figures
Number of Products under Development for Abscess, H2 2011
Products under Development for Abscess – Comparative Analysis, H2 2011
Products under Development by Companies, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Late Stage Products, H2 2011
Mid Clinical Stage Products, H2 2011
Assessment by Monotherapy Products, H2 2011
Assessment by Combination Products, H2 2011
Assessment by Route of Administration, H2 2011
Assessment by Stage and Route of Administration, H2 2011
Assessment by Molecule Type, H2 2011
Assessment by Stage and Molecule Type, H2 2011

Customers who bought this item also bought

• Acute Pain - Pipeline Review, H2 2012
• Psoriasis - Pipeline Review, H2 2012
• Smoking Cessation - Pipeline Review, H2 2012
• Fatty Liver Disease - Pipeline Review, H2 2012
• Rheumatoid Arthritis - Pipeline Review, H2 2012
• Obesity - Pipeline Review, H2 2012
• Oral Mucositis - Pipeline Review, H2 2012
• Osteoarthritis - Pipeline Review, H2 2012
• Male Cancer - Pipeline Review, H2 2012
• Allergic Asthma - Pipeline Review, H2 2012